No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
107 |
4. Check minimum number of eventsNone |
107 |
5. Include endpointsNone |
107 |
6. Filter based on genotype QC (FinnGen only) |
99 |
Control definitions (FinnGen only)
- Control exclude
- M13_DORSOPATHY
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Lordosis
based on the number of shared cases.
Similar with more cases:
- Deforming dorsopathies
- Dorsopathies
- Diseases of the musculoskeletal system and connective tissue
- Any operation in hilmo
- Any prescribed medicine buy
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 734 | 405 | 324 |
| Only index persons | 657 | 367 | 290 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.01 |
| Only index persons | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 49.32 | 51.11 | 46.88 |
| Only index persons | 48.27 | 50.05 | 46.00 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 99 | 54 | 45 |
| Unadjusted period prevalence (%) | 0.02 | 0.02 | 0.02 |
| Median age at first event (years) | 48.75 | 47.87 | 49.80 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 102
- Matched controls
- 1020
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
M40.5
ICD-10 Finland
Lordosis, unspecified
+∞
74.3
62
*
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
17.2
45.9
50
54
M07.3*L40.5
ICD-10 Finland
Other psoriatic arthropathies
126.5
43.2
44
6
L40.5
ICD-10 Finland
Arthropathic psoriasis
140.2
41.6
42
5
A07EC01
ATC
sulfasalazine; oral, rectal
21.7
39.2
33
22
L04AX03
ATC
methotrexate; systemic
13.1
33.3
40
48
L01BA01
ATC
methotrexate; systemic
54.2
24.2
28
7
M07.3
ICD-10 Finland
Other psoriatic arthropathies
293.2
23.7
23
*
D07XC01
ATC
betamethasone; topical
9.0
22.7
35
56
D05AX02
ATC
calcipotriol; topical
33.1
22.4
29
12
313
Kela drug reimbursment
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab, tocilizumab and ustekinumab (rheumatoid diseases)
46.1
18.5
22
6
D05AX52
ATC
calcipotriol, combinations; topical
15.7
17.5
29
25
M40.4
ICD-10 Finland
Other lordosis
+∞
17.2
16
*
281
Kela drug reimbursment
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab and tocilizumab
40.9
16.4
20
6
L04AA13
ATC
[U] leflunomide
54.0
15.6
18
*
L40.0
ICD-10 Finland
Psoriasis vulgaris
18.0
15.5
24
17
E000001, ,
ATC
5.6
15.4
40
105
7372A
ICD-9 Finland
Curvature of spine, Lordosis (acquired)
+∞
13.9
13
*
TNX10
NOMESCO Finland
Arthrocentesis, unspecified region, unspecified region
12.4
13.7
25
26
M51.3
ICD-10 Finland
Other specified intervertebral disc degeneration
46.8
13.6
16
*
M48.0
ICD-10 Finland
Spinal stenosis
46.8
13.6
16
*
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
12.7
13.4
24
24
N03AX16
ATC
[U] pregabalin
5.7
13.2
30
69
M51.1
ICD-10 Finland
Lumbar and other intervertebral disc disorders with radiculopathy
28.7
13.0
17
7
D07AD01
ATC
clobetasol; topical
5.1
12.9
35
94
D07AC01
ATC
betamethasone; topical
4.5
12.7
59
240
L04AB01
ATC
etanercept; parenteral
53.5
12.2
14
*
M07.0*L40.5
ICD-10 Finland
Distal interphalangeal psoriatic arthropathy
+∞
11.7
11
*
D05AX03
ATC
calcitriol; topical
40.1
11.6
14
*
N02AX02
ATC
tramadol; systemic, rectal
4.1
11.2
55
228
H02AB06
ATC
prednisolone; systemic
4.2
11.0
68
330
L04AA01
ATC
[U] ciclosporin
122.0
10.6
11
*
E0000UV, ,
ATC
3.7
9.5
61
294
M07.0
ICD-10 Finland
Distal interphalangeal psoriatic arthropathy
+∞
9.5
9
*
ABC36
NOMESCO Finland
Decompression of lumbar nerve roots
+∞
9.5
9
*
M073, M405,
ICD-10 Finland
+∞
9.5
9
*
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
10.9
8.7
16
17
L88
ICPC
Rheumatoid/seropositive arthritis
12.3
8.6
15
14
NA3BG
NOMESCO Finland
Lumbar spine MRI examination with high intensity magnet
16.3
8.5
13
9
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
4.4
8.2
24
67
M17.1
ICD-10 Finland
Other primary gonarthrosis
3.7
7.9
31
107
NA3CG
NOMESCO Finland
Lumbar spine extensive MRI examination with high intensity magnet
48.9
7.8
9
*
L04AB04
ATC
adalimumab; parenteral
27.4
7.7
10
*
M54.4
ICD-10 Finland
Lumbago with sciatica
4.3
7.5
22
61
NGB20
NOMESCO Finland
Primary total prosthetic replacement of knee joint without patellar part
4.7
7.5
19
47
SPAT1229
SPAT
Assessment of need for aid
9.0
7.4
15
19
N03AX12
ATC
[U] gabapentin; oral
4.5
7.4
20
52
377
Kela drug reimbursment
Apremilast and dimethyl fumarate (psoriasis)
+∞
7.4
7
*
NG1AA
NOMESCO Finland
Knee X-ray examination without contrast
4.4
7.4
21
57
E000002, ,
ATC
4.2
7.3
22
62
M43.1
ICD-10 Finland
Spondylolisthesis
32.6
7.3
9
*
D07AC13
ATC
mometasone; topical
3.2
7.2
39
164
M54.5
ICD-10 Finland
Low back pain
3.1
6.9
40
174
M02AA10
ATC
ketoprofen; topical
4.0
6.9
22
65
M17.5
ICD-10 Finland
Other secondary gonarthrosis
43.0
6.9
8
*
D05AA
ATC
Tars
43.0
6.9
8
*
M01CB01
ATC
sodium aurothiomalate; parenteral
43.0
6.9
8
*
A02BC03
ATC
lansoprazole; oral
3.2
6.8
36
149
J01FF01
ATC
clindamycin; systemic
3.1
6.7
39
170
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
6.4
6.7
17
31
SPAT1254
SPAT
Administration of medicine
3.9
6.6
22
67
M05.8
ICD-10 Finland
Other seropositive rheumatoid arthritis
7.1
6.5
15
24
J01DA09
ATC
[U] cefadroxil
3.1
6.4
36
153
G47.3
ICD-10 Finland
Sleep apnoea
3.2
6.4
33
134
M54.9
ICD-10 Finland
Dorsalgia, unspecified
4.7
6.4
16
39
M47.2
ICD-10 Finland
Other spondylosis with radiculopathy
+∞
6.3
6
*
M43.0
ICD-10 Finland
Spondylolysis
+∞
6.3
6
*
6960A
ICD-9 Finland
Psoriasis and similar disorders, Psoriatic arthropathy
+∞
6.3
6
*
D01AE15
ATC
terbinafine; topical
7.5
6.3
14
21
TPH04
NOMESCO Finland
Cathetrisation of vein
3.2
6.3
31
122
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
2.9
6.3
42
197
SPAT1253
SPAT
Initiation, adjustment, discontinuation or repetition of medication
3.1
6.1
33
137
D07AB02
ATC
hydrocortisone butyrate; topical
2.9
6.1
38
171
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
72
421
3.41
7.63
5.4
3.3
0.00
0.00
estimate
-0.00
14
95
80
505
3.71
7.35
16.4
11.4
3.70
4.02
e9/l
1.06
75
434
72
429
3.31
7.23
5.4
3.3
0.00
0.00
estimate
-0.00
12
85
69
425
2.93
6.10
5.6
3.3
0.00
0.00
estimate
-0.00
14
90
33
171
2.37
3.76
6.2
3.0
1.02
1.02
kg/l
0.42
25
101
55
355
2.19
3.69
6.3
5.2
34.73
35.53
g/l
0.50
49
338
60
401
2.21
3.69
10.3
7.8
1.22
1.22
mmol/l
0.15
54
354
27
129
2.49
3.66
1.1
1.3
26.56
2.41
u/ml
—
8
47
40
228
2.24
3.64
6.0
3.3
0.00
0.00
estimate
-0.00
14
85
51
325
2.14
3.48
5.8
3.1
0.00
0.00
estimate
-0.00
11
78
14
49
3.15
3.34
6.7
4.0
2.93
2.61
mmol/l
—
7
38
8
16
5.33
3.12
2.9
1.4
—
—
—
0
0
7
12
6.17
3.07
2.0
1.3
—
—
—
0
0
40
242
2.07
3.04
4.7
2.9
0.00
0.00
estimate
-0.00
12
69
25
126
2.30
2.98
3.5
2.9
0.90
1.00
e6/l
0.09
20
74
8
19
4.47
2.74
1.4
1.2
—
—
—
0
0
12
41
3.18
2.73
8.5
17.2
24.81
25.00
mmol/l
0.08
12
41
22
109
2.30
2.72
9.1
6.7
1.16
1.07
mmol/l
0.51
22
100
6
11
5.72
2.58
1.3
1.1
—
—
—
0
0
16
70
2.52
2.57
3.7
2.3
0.04
1.45
e6/l
0.56
16
65
22
112
2.23
2.55
3.9
3.2
0.99
3.67
e6/l
1.11
17
62
26
143
2.10
2.49
1.2
1.3
19.72
26.64
iu/ml
—
6
52
7
17
4.34
2.40
1.1
1.5
—
—
—
0
0
7
17
4.34
2.40
1.1
1.5
—
—
—
0
0
5
8
6.50
2.40
1.2
1.1
—
—
—
0
0
5
8
6.50
2.40
1.2
1.1
—
—
—
0
0
5
8
6.50
2.40
1.2
1.1
—
—
—
0
0
5
8
6.50
2.40
1.2
1.1
—
—
—
0
0
5
9
5.77
2.24
1.2
1.1
—
—
—
0
0
5
9
5.77
2.24
1.2
1.1
—
—
—
0
0
6
14
4.48
2.18
3.0
1.4
—
—
—
0
0
19
97
2.18
2.18
4.2
6.4
208.79
227.34
u/l
0.73
19
92
7
20
3.68
2.09
5.3
2.0
—
—
—
0
0
7
20
3.68
2.09
1.1
1.2
—
—
—
0
0
9
32
2.98
2.06
1.4
1.7
—
—
—
0
0
48
343
1.75
2.04
2.0
1.8
90.16
95.78
pmol/l
0.35
28
178
12
51
2.53
2.04
1.9
1.5
—
—
—
0
0
36
242
1.75
1.86
5.0
3.0
4088.21
1166.37
ng/l
0.77
31
202
20
111
2.00
1.85
3.0
2.2
14.67
23.05
%
4.15
20
106
7
23
3.19
1.83
2.3
1.6
1.14
1.20
g/l
—
7
23
51
380
1.68
1.80
4.3
2.6
—
—
estimate
—
0
0
7
24
3.05
1.75
1.1
1.5
—
—
—
0
0
16
86
2.02
1.61
2.6
1.8
—
—
—
0
0
6
20
3.12
1.60
1.3
1.8
—
—
—
0
0
6
20
3.12
1.60
2.8
1.6
—
—
—
0
0
95
866
2.41
1.60
29.5
13.1
17.00
24.16
mg/l
2.57
86
681
5
15
3.45
1.54
1.2
1.7
—
—
—
0
0
5
15
3.45
1.54
2.0
1.1
—
—
—
0
0
13
66
2.11
1.51
2.0
1.5
—
—
—
0
0
42
310
1.60
1.48
6.0
3.4
27.13
66.54
ng/l
1.34
33
218
6
22
2.83
1.45
3.2
1.6
—
—
—
0
0
6
22
2.83
1.45
1.0
1.1
—
3.24
—
0
5
30
204
1.67
1.45
4.5
2.2
—
—
—
0
0
19
114
1.82
1.40
1.6
1.5
763.00
1159.63
nmol/l
1.32
13
88
6
23
2.71
1.39
1.0
1.2
—
—
—
0
0
6
23
2.71
1.39
1.0
1.1
—
—
—
0
0
16
91
1.90
1.38
2.6
1.8
—
—
—
0
0
76
665
1.56
1.13
3.4
4.0
14.47
14.75
pmol/l
0.44
70
614
9
45
2.09
1.08
2.1
2.7
1.31
1.29
%
—
9
45
19
125
1.64
1.03
3.3
2.0
—
—
—
0
0
16
102
1.67
0.97
4.9
8.6
105.44
105.42
mmol/l
0.01
16
102
6
27
2.30
0.95
1.7
1.5
—
—
—
0
0
8
46
1.80
0.85
1.9
3.3
4.63
4.50
pmol/l
—
8
41
6
32
1.93
0.83
3.7
1.6
—
—
—
0
0
21
151
1.49
0.79
2.0
3.2
2.47
2.45
mmol/l
0.34
16
136
5
23
2.23
0.77
3.0
2.0
—
—
—
0
0
5
23
2.23
0.77
1.0
1.1
—
—
—
0
0
5
23
2.23
0.77
1.0
1.1
—
—
—
0
0
5
25
2.05
0.74
3.0
2.3
—
—
—
0
0
5
26
1.97
0.71
3.6
2.5
—
—
—
0
0
5
27
1.89
0.69
3.2
2.3
—
—
—
0
0
64
568
1.34
0.69
3.8
3.1
—
—
—
0
0
0
21
0.00
0.61
0.0
1.5
—
1.26
—
0
13
0
21
0.00
0.61
0.0
1.5
—
0.97
—
0
13
0
21
0.00
0.61
0.0
1.5
—
0.96
—
0
13
34
280
1.32
0.60
4.0
4.0
30.05
6.65
mg/mmol
0.62
25
171
0
23
0.00
0.59
0.0
1.7
—
58.82
—
0
18
6
36
1.71
0.58
1.7
1.4
26.00
39.11
nmol/l
—
6
36
20
153
1.38
0.56
7.0
4.2
0.86
0.81
mmol/l
0.79
20
148
6
39
1.57
0.54
1.5
1.5
—
—
—
0
0
8
55
1.49
0.44
1.1
1.4
43.65
20.92
iu/l
—
8
45
5
35
1.45
0.40
6.8
2.5
24.70
25.99
mmol/l
—
5
35
92
887
1.38
0.36
29.0
15.5
139.33
139.81
mmol/l
1.16
92
864
6
44
1.39
0.35
1.0
1.4
—
—
—
0
0
92
888
1.37
0.35
29.3
15.6
3.98
3.97
mmol/l
0.15
92
866
6
90
0.65
0.34
23.0
6.1
—
—
—
0
0
11
84
1.35
0.31
3.7
2.7
—
—
—
0
0
20
236
0.81
0.31
2.6
3.6
22.81
22.66
%
—
7
112
9
73
1.26
0.26
1.3
1.6
—
—
—
0
0
47
433
1.16
0.26
4.0
2.6
97.37
135.65
ug/l
0.87
47
404
96
936
1.44
0.25
23.6
11.0
27.07
26.60
u/l
0.12
96
916
0
12
0.00
0.21
0.0
1.7
—
13.42
—
0
12
0
12
0.00
0.21
0.0
1.3
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
0
14
0.00
0.20
0.0
1.2
—
—
—
0
0
0
14
0.00
0.20
0.0
1.2
—
—
—
0
0
26
288
0.87
0.20
4.2
4.6
1.30
3.02
ug/l
0.93
21
259
10
81
1.26
0.19
1.5
1.7
—
—
—
0
0
33
354
0.90
0.15
2.6
1.9
1.66
1.33
mmol/l
0.93
24
292
88
897
0.86
0.13
5.8
5.5
2.87
2.76
mmol/l
0.50
83
831
23
212
1.11
0.11
1.2
1.3
1.07
1.98
u/ml
—
6
52
83
813
1.11
0.10
4.7
4.8
1.75
1.89
mu/l
0.53
78
754
5
43
1.17
0.10
6.2
13.2
0.84
1.34
%
—
5
43
65
634
1.07
0.08
3.6
3.1
69.54
50.97
u/l
0.55
65
599
95
938
1.19
0.07
34.5
17.2
85.07
76.23
umol/l
0.50
95
925
10
91
1.11
0.04
3.0
2.1
10.41
14.67
nmol/l
—
10
83
85
840
1.07
0.04
4.8
4.1
1.48
1.25
mmol/l
2.08
79
772
11
101
1.10
0.04
6.7
3.0
16.50
7.73
umol/l
0.32
11
88
89
883
1.06
0.01
5.4
4.9
4.76
4.69
mmol/l
0.24
84
821
17
171
0.99
0.00
1.8
1.5
—
—
—
0
0
88
879
1.01
0.00
5.5
4.8
1.38
1.48
mmol/l
1.70
82
813
13
126
1.04
0.00
1.7
1.4
—
—
—
0
0
97
967
1.06
-0.00
42.8
21.1
40.56
40.72
%
0.13
97
954
0
7
0.00
-0.00
0.0
2.4
—
6.54
—
0
7
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.9
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
2.8
—
100.17
—
0
6
0
6
0.00
-0.00
0.0
1.0
—
23.77
—
0
6
0
5
0.00
-0.00
0.0
1.0
—
1612.40
—
0
5
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
(40770918) von Willebrand factor (vWf).activity actual/normal in Platelet poor plasma by Immunoassay
0
6
0.00
-0.00
0.0
1.0
—
167.33
—
0
6
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
97
967
1.06
-0.00
43.1
20.7
134.41
136.72
g/l
0.77
97
955
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.5
—
12.67
—
0
6
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint M13_LORDOSIS and mortality.
Females
No dataMales
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| M13_LORDOSIS | 1.788 [1.23, 2.6] | 0.002 |
| Birth year | 0.984 [0.97, 0.99] | 0.002 |
During the follow-up period (1.1.1998 — 31.12.2019), 68 out of 251 males with M13_LORDOSIS died.
Mortality risk
Mortality risk for people of age
years, who have M13_LORDOSIS.| N-year risk | Females | Males |
|---|---|---|
| 1 | No data | 0.306% |
| 5 | No data | 1.995% |
| 10 | No data | 5.138% |
| 15 | No data | 9.005% |
| 20 | No data | 15.167% |
Relationships between endpoints
↥Index endpoint: M13_LORDOSIS – Lordosis
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data